Literature DB >> 17849464

Successful treatment with rituximab in a patient with an acquired factor V inhibitor.

Agnes Lebrun1, Catherine Leroy-Matheron, Jean-Benoit Arlet, Pablo Bartolucci, Marc Michel.   

Abstract

Rituximab has already been successfully used to treat immune-mediated bleeding disorders such as acquired factor VIII inhibitor. We report here a case of severe acquired factor V (FV) inhibitor deficiency due to FV inhibitor which has been dramatically improved after rituximab.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 17849464     DOI： 10.1002/ajh.21056

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  9 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Isolated factor V deficiency in a patient with elevated PT and aPTT during routine pre-operative laboratory screening.

Authors:  Keyur Thakar; Kaushal Parikh; Yamei Chen; Delong Liu
Journal:  Stem Cell Investig       Date:  2014-02-08

3.  Complete response of acquired FV inhibitor to rituximab.

Authors:  Edmond S K Ma; Raymond H S Liang; Kent-Man Chu; George K K Lau
Journal:  Int J Hematol       Date:  2015-01-24       Impact factor: 2.490

4.  Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature.

Authors:  Qing-ya Cui; Hong-shi Shen; Tian-qin Wu; Hai-fei Chen; Zi-qiang Yu; Zhao-yue Wang
Journal:  Drug Des Devel Ther       Date:  2015-04-24       Impact factor: 4.162

5.  Acquired Factor V Inhibitors in a Patient with End-stage Renal Disease.

Authors:  Atsushi Kitazawa; Hideo Misawa; Katsuhiro Nagahori; Ryo Koda; Atsunori Yoshino; Shinya Kawamoto; Tetsuro Takeda
Journal:  Intern Med       Date:  2016-12-01       Impact factor: 1.271

6.  Acquired factor V inhibitors after allogeneic hematopoietic stem cell transplantation in a dog.

Authors:  Joseph Masciana; Nathan Peterson; John Chretin
Journal:  J Vet Intern Med       Date:  2020-07-20       Impact factor: 3.333

7.  Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety.

Authors:  Paul Ness; Michael Creer; George M Rodgers; Joseph J Naoum; Kenneth Renkens; Stacy A Voils; W Allan Alexander
Journal:  Patient Saf Surg       Date:  2009-05-22

8.  A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors.

Authors:  Yasuko Kadohira; Shinya Yamada; Tomoe Hayashi; Eriko Morishita; Hidesaku Asakura; Akitada Ichinose
Journal:  Int J Hematol       Date:  2018-04-02       Impact factor: 2.319

9.  Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up.

Authors:  Dustin Anderson; Cecile Phan; Wendy S Johnston; Zaeem A Siddiqi
Journal:  Ann Clin Transl Neurol       Date:  2016-05-25       Impact factor: 4.511
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.